RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Revenue growth (%)

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$109.6B
P/E ratio
SummaryFinancials
Period EndRevenue growth (%) YoY (%)
Dec 31, 202411.7+10.94%
Dec 31, 202310.5-41.32%
Dec 31, 202217.9-18.81%
Dec 31, 202122.1-55.04%
Dec 31, 202049.1+34.11%
Dec 31, 201936.6+62.91%
Dec 31, 201822.5-51.39%
Dec 31, 201746.2-28.80%
Dec 31, 201664.9-16.66%
Dec 31, 201577.9-249.41%
Dec 31, 2014-52.1+152.59%
Dec 31, 2013-20.6-350.06%
Dec 31, 20128.3-99.07%
Dec 31, 2011883.9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)